Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 83 84 85 86 87 88 »» | Laatste | Omlaag ↓
  1. [verwijderd] 29 april 2009 12:56

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    spvthijs schreef:

    Heb me idd 1x negatief uitgelaten. Daarvoor excuus. Als het goed is het enige negatieve geluid door mij ooit gespuit. Gr Thijs
    thijs!
    meer dan geaccepteerd, was mijn enige kanttekening en ik heb daarvoor je ook als een toevoeging aan het forum gezien. Een excuus is dan ook snel en gemeend aanvaard.

    Mbt dendreon, puts na de data presentatie van gister minder nodig. Zou eerder een call optie stategie bekijken. Downwaards risico afdekken minder nodig en relatief duur tov risico. Ben zelf geen optie handelaar, ik vraag als ik ergens interese heb meestal aan US contacten die niets anders doen, maar die geeft ene keer eerder thuis dan de andere keer.
  3. [verwijderd] 29 april 2009 15:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tnks voor de info Crakcked. Zijn die puts ook beschikbaar voor fondsen a la Dendreon?
    Het blijft idd riskante business. Vindt het daarnaast ook ongepast want we hebben het hier wel over een middel tegen kanker. Ironisch genoeg een ziekte waaraan mijn moeder 8 jaar geleden op 47jarige leeftijd aan is overleden.

    Ben benieuwd vandaag. Ik denk dat ik maar verkooop want dan steek ik iig weer een winst op en sta ik quitte voor het beleggingsjaar 2009.
  4. [verwijderd] 29 april 2009 17:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    spvthijs schreef:

    Tnks voor de info Crakcked. Zijn die puts ook beschikbaar voor fondsen a la Dendreon?
    Het blijft idd riskante business. Vindt het daarnaast ook ongepast want we hebben het hier wel over een middel tegen kanker. Ironisch genoeg een ziekte waaraan mijn moeder 8 jaar geleden op 47jarige leeftijd aan is overleden.

    Ben benieuwd vandaag. Ik denk dat ik maar verkooop want dan steek ik iig weer een winst op en sta ik quitte voor het beleggingsjaar 2009.
    juist dendreon, een van de weinige biotech waar juist VEEL opties in zijn en waar erg veel in word verhandeld,
    (met navenant extra gemanipuleer tbv optiemarkt erin, met ook invloed op de aandelen)
    Met oa Aschoff met zijn leugenachtige draaien in verleden en keiharde bear trades op dendreon.

    meeste smallcap biotech geen opties
    maar dendreon had er al veel toen het nog 300-500mln markwaarde had
  7. [verwijderd] 29 mei 2009 22:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    [quote=vastgoedkoning]
    gaat het nog verder up of hebben we het gehad?
    [/quote]
    +61 cents, $21,65
    P.
    Last Trade: $22.67
    Change: 0.67 (+3.05%)

    5/29/2009 2:30 PM
    Keywords: DNDN

    Bullish sentiment is on the rise toward Dendreon Corporation (DNDN). During the past 10 days, traders on the International Securities Exchange (ISE) have bought to open 21,335 calls on the biotech stock, compared to 5,416 puts. The equity's 10-day ISE call/put volume ratio of 3.94 ranks higher than 83.7% of other such readings taken during the past year, revealing that bullish bets on DNDN have crossed the tape at a faster pace less than 17% of the time.

    In the June series, call players have set their sights on the 25 and 30 strikes. The latter is home to peak front-month call open interest of 13,153 contracts, while the former carries a respectable accumulation of 12,554 contracts.

    Meanwhile, the most popular put option in the June series is the 20 strike, with 12,599 contracts in residence.

    With DNDN trading near $22.50, all three of these heavily traded options are out of the money. In fact, it seems that both bullish and bearish speculators might be frustrated with the stock's recent price action. After spiking sharply in mid-April on the heels of positive Provenge data, DNDN has spent the past month trading sideways between $19 and $23.

    Of course, given the stock's propensity for wild swings, it's probably too soon to predict where DNDN will be trading on June 19, when all of these options will expire.

    www.schaeffersresearch.com/commentary...

    ----------------------------------------------------

    Merriman Curhan Ford's Pantginis is a fan of Dendreon, a company that until Apr. 13 might have seemed likely to run out of funds before getting a drug approved. That's when it announced a successful trial of its prostate cancer vaccine, Provenge. Shares shot up from less than 3 to 21, but Pantginis thinks the stock is still undervalued. After talking with numerous doctors in the field, he thinks Provenge will win substantial sales for the company and that the stock is worth 33 or more.

    www.businessweek.com/blogs/personal_f...

    Mvg,
    Skip
  10. [verwijderd] 14 september 2009 19:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Real-Time Quote $26.83 2.99 +12.54%

    Dendreon (DNDN) Higher On Renewed Takeover Talk

    Shares of Dendreon Corp. (Nasdaq: DNDN) are jumping higher on healthy volume today on resurfaced rumors the company could be the target of a takeover bid. At noon, shares are up over 8% and volume is twice normal already.

    Takeover talk has been swirling around Dendreon since April when the company announced that its Phase III trial of Provenge met its primary endpoint.

    In July, it was reported that Dendreon retained JP Morgan as financial advisor, but at that point it was thought the appointment was more likely to be related to a partnership deal as opposed to any near-term M&A.

    finance.aol.com/quotes/dendreon-corpo...

    Gr, Skip
  12. [verwijderd] 18 september 2009 14:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The Street:
    www.thestreet.com/story/10600286/3/bu...

    Reacties op Yahoo:
    messages.finance.yahoo.com/Stocks_%28...

    New FDA Guidance Looks Good for Dendreon
    Dendreon(DNDN Quote) has yet to resubmit Provenge to the FDA, but regulators already appear to be supportive.
    The FDA issued new draft guidance for cancer vaccines last night that validate many of the approaches Dendreon took in the design of its clinical trials and the quality control measures it uses to ensure the potency of the prostate cancer vaccine.
    "These are the first FDA statements that acknowledge the validity of Dendreon's regulatory approach for Provenge. The guidance also appears to be almost identical to the approach Dendreon has taken to monitor Provenge activity for quality control," said Deutsche Bank biotech analyst Robyn Karnauskas. She has a buy rating on Dendreon with a $36 price target.
    Dendreon shares rose 7.8% to $28.90 Thursday. The stock has been strong in recent days as investors anticipate the company's analyst meeting on Sept. 24.

    P.
  13. [verwijderd] 12 januari 2010 14:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dendreon Cash Helps Speed Capacity, Europe Deal Leverage

    Last update: 1/11/2010 8:11:25 PM

    By Thomas Gryta
    Of DOW JONES NEWSWIRES
    SAN FRANCISCO (Dow Jones)--Dendreon Corp. (DNDN) said it expects the cash it raised in December to accelerate the completion of its manufacturing facilities and that the cash has given it leverage in finding a European marketing partner for its experimental prostate-cancer treatment.

    The comments came from Dendreon Chief Executive Mitchell Gold at JPMorgan's Healthcare conference in San Francisco on Monday. The Seattle-based drug maker reported last April that the drug successfully prolonged patients' lives, which could make it the first immunotherapy approved for cancer.

    Provenge uses a patient's own cells to prompt the body to fight the disease, leading many to call it a vaccine. Some observers on Wall Street expect it to eventually be a blockbuster drug.

    In applying to the U.S. Food and Drug Administration, Dendreon filed an amendment to its previously rejected marketing application for Provenge, and the agency is expected to respond by May 1.

    An FDA advisory recommended the approval of Provenge in 2007, but the agency requested more data. On Monday, Gold said the company is in "continuous dialogue" with the FDA and received no indication the agency will hold another advisory panel before making its approval decision.

    The company expects to initially produce Provenge at its New Jersey facility, which will initially be at 25% capacity and fully complete in the first half of 2011.

    Meanwhile, it is building other facilities in Atlanta and Los Angeles and had initially expected those to be complete by the end of 2011. It now believes those will be done by mid-2011, citing the $410 million it raised in a stock offering in December. Gold said the company now has about $600 million in cash and can launch Provenge immediately after approval.

    The N.J. facility can produce $60 million to $120 million worth of Provenge, on a sales basis, in the first six months of operating. When complete, the location will produce $500 million to $1 billion of the drug a year. The Los Angeles and Atlanta locations will produce a total of $750 million to $1.5 billion of the drug a year when complete.

    Apart from speeding up its capacity, the recent fundraising may speed up its discussion with potential European partners. Gold said the money gives Dendreon the confidence that it can fully market the drug by itself in the U.S. Potential overseas partners have been pushing to help Dendreon sell it domestically, but now the company has shown them it is serious about its resolve to keep control in the U.S. Unlike making a pill, Provenge's production involves taking a patient's cells, shipping them to the company for processing, then returning them to a physician to be delivered via intravenous infusion.

    This entire process must be performed three times over four weeks. Since the positive data, Dendreon has been preparing to transform into a commercial enterprise. Despite the lack of partnership, the company has tapped key figures from the pharmaceutical world. Last month, it named Bayer AG (BAYN.XE, BAYRY) executive Hans Bishop as chief operating officer, and earlier last year named Ian Clark, chief executive of Roche Holding AG's (RHHBY) Genentech unit, and Pedro Granadillo, former senior vice president of global manufacturing at Eli Lilly & Co. (LLY), to its board of directors.

    -Thomas Gryta; Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com (END)

    Dow Jones NewswiresJanuary 11, 2010 20:11 ET (01:11 GMT)

    DRW
  14. [verwijderd] 2 maart 2010 16:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    *DENDREON'S PROVENGE IS SCHEDULED FOR FDA ACTION BY MAY 1
    *FDA SPOKESWOMAN SHELLY BURGESS SAYS NO PLANS FOR ADVISORY PANEL
    *DENDREON'S PROVENGE WON'T FACE U.S. FDA PANEL, SPOKESWOMAN SAYS

    + 6% op 34,50

    P.
  15. [verwijderd] 4 maart 2010 12:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Data to be Presented at ASCO-GU Annual Symposium --
    SEATTLE, March 3, 2010 /PRNewswire via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study demonstrating that PROVENGE(R) (sipuleucel-T) extends overall survival in men with metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). The data will be presented at the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium (ASCO-GU) in San Francisco on Friday, March 5 at 1:45 pm PT.

    A sensitivity analysis performed with longer-term follow-up (36.5 months) and additional events (349 deaths) collected at the time of study closure demonstrated that PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death [HR=0.759] and a p-value of 0.017.

    As previously reported in a primary analysis (34.1 months median follow-up; 331 deaths), the IMPACT study met its pre-specified primary endpoint of significantly improving overall survival compared to placebo, demonstrating that PROVENGE increased three-year survival by 38 percent compared to placebo (31.7 percent vs 23.0 percent), extending median survival by 4.1 months compared to placebo (25.8 months vs. 21.7 months), with a 22.5 percent reduction in the risk of death [HR=0.775] and a p-value of 0.032.

    In addition, new analyses demonstrated that the median predicted survival of the two treatment arms using the Halabi model were well balanced (20.3 months for PROVENGE vs 21.2 months for placebo). Furthermore, in an analysis in which patients were censored at the time of docetaxel use, the PROVENGE treatment effect remained strong [HR=0.649].

    As previously reported, the most common adverse reactions were chills, fever, headache, aches, influenza-like illness and sweating.

    "The results from the IMPACT study corroborate earlier studies with sipuleucel-T in demonstrating an improvement in overall survival for men with metastatic castration resistant prostate cancer. This is the first therapeutic vaccine to demonstrate a survival benefit in cancer," said Philip Kantoff, M.D., Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, and Chief Clinical Research Officer at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and principal investigator of the IMPACT study. "Furthermore, the results of this study validate cancer immunotherapy as an entirely new treatment paradigm that can provide patients with a clinically meaningful survival benefit coupled with a well-tolerated safety profile."

  18. [verwijderd] 12 maart 2010 20:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Real-Time: $37.04 Up 1.03 (+2.86%)
    Change: Up 0.36 (0.99%)
    Prev Close: $36.01
    Day's Range: $36.36 - $36.79
    52wk Range: $2.80 - $37.05

    Dendreon (DNDN): There's no keeping Dendreon out of the news, Robert Baird initiating it Outperform with a $48 price objective. The broker sees significant upside potential ahead of Provenge's likely launch. See also Dendreon and the Prostate Cancer Battle.

    www.minyanville.com/businessmarkets/a...

    Skip
  19. [verwijderd] 26 maart 2010 15:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dendreon Corporation(NasdaqGM: DNDN)

    Real-Time: $37.33 Up 0.72 (+1.97%)

    52wk Range: $4.02 - $38.12

    Dendreon To Celebrate May Day.

    In much of the world, May Day is a festive event. Worldwide, Mayday is a call for help.

    For Dendreon (DNDN), May 1, May Day, likely will be a celebration, not a distress call. On that date, the company is expected to get Food and Drug Administration approval for its prostate cancer drug, Provenge.

    It's been a long slog for Seattle-based Dendreon, which has no products on the market yet. Founded in 1992 and publicly traded since 2000, the firm has pinned its future on the technology behind Provenge.

    nvestors who bet on Dendreon a year ago have done well. The stock traded near 4 last March and now trades near an all-time high of 37, near an all-time high.

    The drug is in a class known as therapeutic vaccine. It differs from vaccines that prevent disease, like Merck's (MRK) Gardasil, a vaccine against a cause of cervical cancer, human papilloma virus.

    Provenge sparks the body's own immune system to fight at least one type of prostate cancer in men for whom all other treatments have failed. It's called androgen-dependent prostate cancer.

    That's the condition for which the FDA is expected to give approval.

    The company hopes Provenge will be a platform drug from which a wider range of cancer conditions can be treated, says Howard Liang, an analyst with Leerink Swann who rates the stock outperform, or buy.

    Dendreon didn't respond to IBD's interview requests. Many biotech and medtech companies go silent in the weeks before an FDA verdict is expected.

    Provenge had to get past a lot of doubters, says Dr. Mark Monane, a medical doctor and analyst with Needham & Co. His employer does business with Dendreon.

    But Provenge does what the company claims, Monane says. "It's really it," he said. He rates the stock a buy.

    The FDA was so skeptical that Dendreon had to conduct three sets of phase three trials, Monane says. The last one, released in April 2009, appears to have cemented Provenge's credibility.

    Data from multiple clinical trials show that Provenge increased three-year survival rates by 40% compared with a placebo. In the war on cancer, that's big, though it's not a cure.

    "You don't see tumor shrinkage, but Provenge does promote survival," Liang said. He has a price target of 40 on the stock.

    The treatment process is unusual. Blood is drawn from the patient and specific cells are shipped to a Dendreon plant. There, Provenge is added to bolster the sample's ability to fight cancer cells.

    he Provenge-fortified mixture is sent back for infusion in the patient. Three treatments are required. The company calls its technology active cellular immunotherapy.

    "It's a very involved and complex process," Monane said.

    While the various elements of the process are done every day in the U.S., he says, this is the first time they've been unified for a specific disease.

    One bonus: no significant side effects and no toxicity. That in itself is a marked difference from many cancer treatments, such as chemotherapy.

    Dendreon is so confident that Provenge will win approval that it has built two new plants to meet the demand, adding one in Atlanta and one in Los Angeles to the plant it already had in New Jersey. And it has been expanding its lab and office space in Seattle.

    The firm has an eager market, Monane says. About 100,000 Americans have metastatic prostate cancer and 30,000 die each year.

    On a global basis, the market could be as much as $2 billion a year, he says. Dendreon hasn't given a cost estimate, but analysts have estimated the treatment could cost around $50,000.

    The company will market Provenge itself in the U.S., but it's keeping specifics close to its vest, Liang says.

    The firm needs to convince just 8,000 specialists around the country. And they're already aware Provenge is coming, Monane says. "Physicians will create high demand for the drug," he said.

    Dendreon will license Provenge abroad, Liang says. "They're talking to potential partners," he said.

    Could Provenge be approved for earlier-stage prostate cancers, or for other cancers?

    The company has plans to prove Provenge and related products can work for more patients. And Provenge itself might work on earlier-stage prostate cancers.

    "When you've got something good, you run with it," Monane said.

    www.investors.com/NewsAndAnalysis/Art...

    Skip
  20. [verwijderd] 29 april 2010 18:39

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Halted op $45.51 nadat de koers plotseling opveerde.

    NASDAQ Last Sale
    45.51 5.89 +14.87%
    Volume
    3,644,940
    Previous Close
    $ 39.62
    Today's High
    $ 47.3200
    Today's Low
    $ 39.4000

    Skip
1.743 Posts
Pagina: «« 1 ... 83 84 85 86 87 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.200
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.526
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.654
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.996
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.330
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.721
AMG 971 133.066
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.925
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.572
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.079
ASML 1.766 106.016
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 07 februari

    1. Aperam Q4-cijfers
    2. Orange Belgium Q4-cijfers
    3. Crédit Agricole Q4-cijfers (Fra)
    4. TotalEnergies Q4-cijfers (Fra)
    5. Novo Nordisk Q4-cijfers (Dee)
    6. Industriële productie december (Dld)
    7. Handelsbalans december (Dld)
    8. Harley-Davidson Q4-cijfers (VS)
    9. Banengroei en werkloosheid januari (VS) Banengroei: 170K, werkloosheid: 4,1%, uurlonen: +3,8% YoY volitaliteit verwacht
    10. Consumentenvertrouwen (Universiteit v Michigan) februari vlpg (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda